Abstract
The therapeutic landscape of multiple myeloma (MM) has been rapidly evolving with the development of newer modalities such as chimeric antigen receptor T-cell (CAR-T) therapies. Currently, there are two CAR-T cell products approved by the U.S. Food and Drug Administration for MM, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Both products target B cell maturation antigen, or BCMA, on the surface of MM cells and showed impressive results in pivotal clinical trials, with overall response rates of 73% and 97%, respectively.1 2 Nonetheless, to date, MM remains largely incurable, with post BCMA-directed therapy relapse posing a major hurdle.
Original language | English (US) |
---|---|
Article number | e005822 |
Journal | Journal for immunotherapy of cancer |
Volume | 10 |
Issue number | 9 |
DOIs | |
State | Published - Sep 22 2022 |
Externally published | Yes |
Keywords
- Immunity, Cellular
- Immunotherapy
- Immunotherapy, Adoptive
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Molecular Medicine
- Oncology
- Pharmacology
- Cancer Research